Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Zanolimumab

EU orphan designation number: EU/3/07/438   
Active ingredient: Zanolimumab
Indication: Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Sponsor: TenX Biopharma Ltd
19-20 Bourne Court, Southend Road, Woodford Green, Essex IG8 8HD, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/03/2007 Centralised Orphan - Designation EMEA/OD/096/06 (2007)1322 of 20/03/2007
14/03/2008 Centralised Orphan - Transfer of orphan designation EMEA/OD/096/06/T/01 (2008)1064 of 11/03/2008
30/09/2010 Centralised Orphan - Transfer of orphan designation EMEA/OD/096/06/T/02 (2010)6804 of 28/09/2010